Search International and National Patent Collections

1. (WO2018039490) USE OF GENOMIC SIGNATURES TO PREDICT RESPONSIVENESS OF PATIENTS WITH PROSTATE CANCER TO POST-OPERATIVE RADIATION THERAPY

Pub. No.:    WO/2018/039490    International Application No.:    PCT/US2017/048486
Publication Date: Fri Mar 02 00:59:59 CET 2018 International Filing Date: Fri Aug 25 01:59:59 CEST 2017
IPC: C12Q 1/68
G01N 33/48
G01N 33/574
C40B 40/06
G06F 19/20
Applicants: GENOMEDX BIOSCIENCES, INC.
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventors: DAVICIONI, Elai
ASHAB, Hussam, Al-Deen
ERHO, Nicholas
ZHAO, Shuang, G.
CHANG, S., Laura
FENG, Felix, Y.
Title: USE OF GENOMIC SIGNATURES TO PREDICT RESPONSIVENESS OF PATIENTS WITH PROSTATE CANCER TO POST-OPERATIVE RADIATION THERAPY
Abstract:
Methods, compositions, and kits for identifying individuals who will be responsive to post-operative radiation therapy for treatment of prostate cancer are disclosed. In particular, the invention relates to a genomic signature based on expression levels of DNA Damage Repair genes that can be used to identify individuals likely to benefit from post-operative radiation therapy after a prostatectomy.